Sialostatin Mediation Controls Blood-feeding Success of the Tick Ixodes scapularis


This invention offers an environmentally friendly alternative to existing acaricides (pesticides), and relates to vaccines against tick bites and the pathogens that the ticks may transmit.

Bites from the nymphal stage of Ixodes scapularis are associated with Lyme disease transmission in disease-endemic areas of central and eastern US. Ixodes scapularis nymphs are the key vector stage implicated in Lyme disease transmission, mainly due to their small size that makes timely detection difficult. Guinea pig vaccination against sialostatin L2, a secreted Ixodes scapularis salivary protein, can confer nymphal recognition and protection against the tick. Increased rejection rates, prolonged feeding time, and inflammation were observed in the vaccine group, indicating that a protective host immune response was elicited. Moreover, anti-sialostatin L2 titers correlate with weight reduction of nymphs by the end of feeding. These studies suggest that an essential action of sialostatin L2 can be blocked by host humoral immunity.

Potential Commercial Applications: Competitive Advantages:
Use of sialostatin L2 in a multi-component vaccine to protect against tick bites, and the pathogens that the ticks may transmit. 
  • Sialostatin L2 as an anti-tick vaccine will target the vector and therefore confer protection against all the pathogens that may be transmitted by the vector.
  • An environmentally friendly alternative to acaricides.


Development Stage:
The technology is currently in the pre-clinical stage of development.

Inventors:

Michail Kotsyfakis (NIAID)  ➽ more inventions...

Jose Ribeiro (NIAID)  ➽ more inventions...

Jesus Valenzuela (NIAID)  ➽ more inventions...

John Andersen (NIAID)  ➽ more inventions...

Jennifer Anderson (NIAID)  ➽ more inventions...


Intellectual Property:
US Application No. 60/963,332
PCT Application No. PCT/US2008/009075
US Application No. 12/671,703

Publications:
M Kotsyfakis et al. Cutting edge: Immunity against a "silent" salivary antigen of the Lyme vector Ixodes scapularis impairs its ability to feed. J Immunol. 2008 Oct 15;181(8):5209-5212. PubMed abs
M Kotsyfakis et al. Selective cysteine protease inhibition contributes to blood-feeding success of the tick Ixodes scapularis. J Biol Chem. 2007 Oct 5;282(40):29256-29263. PubMed abs
M Kotsyfakis et al. Antiinflammatory and immunosuppressive activity of sialostatin L, a salivary cystatin from the tick Ixodes scapularis. J Biol Chem. 2006 Sep 8;281(36):26298-26307. PubMed abs

Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases / Laboratory of Malaria and Vector Research / Vector Biology Section is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize potential applications based on the above mentioned patent and in regard to the protection from tick bites and the pathogens they transmit. Please contact Charles Rainwater, NIAID/OTD, at 301-435-8617/or crainwater@niaid.nih.gov for more information.


Licensing Contact:
Admin. Licensing Specialist (ALS),
Email:
Phone:

OTT Reference No: E-289-2007-0
Updated: Feb 2, 2009